### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

## FORM 8-K

#### **CURRENT REPORT**

#### PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 9, 2023

# AMNEAL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

(Former Name or larm 8-K filing is intendent to Rule 425 under Rule 14a-12 under the	er the Securities Act (17 CFR 23) ne Exchange Act (17 CFR 240.1	code: (908) 947-3120  ince Last Report)  ne filing obligation of the registrant under any of the following  0.425)  4a-12)				
(Former Name or larm 8-K filing is intendent to Rule 425 under Rule 14a-12 under the	Bridgewater, NJ 08807 principal executive offices) e number, including area N/A Former Address, if Changed S added to simultaneously satisfy the securities Act (17 CFR 230 are Exchange Act (17 CFR 240.1)	code: (908) 947-3120  ince Last Report)  ne filing obligation of the registrant under any of the following  0.425)  4a-12)				
(Former Name or larm 8-K filing is intendent to Rule 425 under Rule 14a-12 under the	e number, including area N/A Former Address, if Changed S  nded to simultaneously satisfy the securities Act (17 CFR 230 ne Exchange Act (17 CFR 240.1)	code: (908) 947-3120  ince Last Report)  ne filing obligation of the registrant under any of the following  0.425)  4a-12)				
(Former Name or I rm 8-K filing is inten- uant to Rule 425 under Rule 14a-12 under the	N/A Former Address, if Changed S anded to simultaneously satisfy the rest the Securities Act (17 CFR 230 the Exchange Act (17 CFR 240.1)	ince Last Report)  the filing obligation of the registrant under any of the following  0.425)  4a-12)				
rm 8-K filing is intendent of Rule 425 under the Rule 14a-12 under the	Former Address, if Changed S  anded to simultaneously satisfy the securities Act (17 CFR 23)  the Exchange Act (17 CFR 240.1)	ne filing obligation of the registrant under any of the following 0.425) 4a-12)				
uant to Rule 425 unde Rule 14a-12 under th	er the Securities Act (17 CFR 23) ne Exchange Act (17 CFR 240.1	0.425) 4a-12)				
Rule 14a-12 under th	ne Exchange Act (17 CFR 240.1	4a-12)				
	Č ,	, and the second				
cations pursuant to Ru	ule 14d-2(b) under the Exchange	1 (4 T GTD 240 444 24))				
	and I id 2(0) amade the Entertaing	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))				
cations pursuant to Ru	ule 13e-4(c) under the Exchange	Act (17 CFR 240.13e-4(c))				
(b) of the Act:						
60.01 per share	Trading Symbol(s) AMRX	Name of each exchange on which registered New York Stock Exchange				
		ale 405 of the Securities Act of 1933 (§230.405 of this chapter)				
		the extended transition period for complying with any new or $\Box$				
	rant is an emerging glact of 1934 (§240.12b	rant is an emerging growth company as defined in Ruact of 1934 (§240.12b-2 of this chapter).				

#### Item 5.07 Submission of Matters to a Vote of Security Holders.

Amneal Pharmaceuticals, Inc. (the "Company") held its 2023 Annual Meeting of Stockholders (the "Annual Meeting") on May 9, 2023. Each of the proposals was approved, and each of the director nominees was elected, by the vote of the stockholders at the Annual Meeting as follows:

<u>Proposal 1</u>: To elect the following director nominees to hold office until the 2024 Annual Meeting of Stockholders and until their respective successors are elected and qualified:

	For	Against	Abstain	Broker Non-Votes
Emily Peterson Alva	229,279,380	1,816,706	96,495	25,513,061
Deb Autor	229,602,211	1,483,770	106,600	25,513,061
J. Kevin Buchi	197,910,568	33,179,505	102,508	25,513,061
Jeff George	198,211,840	32,879,658	101,083	25,513,061
John Kiely	196,066,358	35,022,385	103,838	25,513,061
Paul Meister	212,151,263	18,932,673	108,645	25,513,061
Ted Nark	228,742,967	2,217,364	232,250	25,513,061
Chintu Patel	229,230,849	1,865,246	96,486	25,513,061
Chirag Patel	229,182,342	1,913,165	97,074	25,513,061
Gautam Patel	227,239,534	3,785,347	167,700	25,513,061
Shlomo Yanai	229,147,164	1,938,034	107,383	25,513,061

<u>Proposal 2</u>: To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers:

For	Against	Abstain	Broker Non-Votes
227,413,821	3,098,184	680,576	25,513,061

Proposal 3: To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023:

For	Against	Abstain	Broker Non-Votes
254,931,713	1,641,294	132,635	0

Proposal 4: To approve the Amended & Restated 2018 Incentive Award Plan:

For	Against	Abstain	Broker Non-Votes
215,730,063	15,006,306	456,212	25,513,061

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 12, 2023 AMNEAL PHARMACEUTICALS, INC.

By: /s/ Jason B. Daly

Name: Jason B. Daly

Title: Executive Vice President, Chief Legal Officer and Corporate

Secretary